Takaisin

Combined oral contraceptive pills in primary dysmenorrhoea

Näytönastekatsaukset
Kalle Saikkonen and Aleksi Raudasoja
3.3.2026

Level of evidence: B

Combined oral contraceptive pills likely reduce pain in primary dysmenorrhoea.

A Cochrane systematic review and meta-analysis «Schroll JB, Black AY, Farquhar C, et al. Combined ...»1 compared combined oral contraceptive pills with placebo, with other OCPs and NSAIDs in the treatment of primary dysmenorrhoea.

Pooled data suggested a moderate impact on dysmenorrhea related pain (SMD −0.58, 95% CI −0.74 to −0.41; I² = 28%; 6 RCTs, n=588). The impact translates to an improvement of 0.8 points on the Total Dysmenorrhoea Score (0-6).

OCPs increased the risk of any adverse events (RR 1.31, 95% CI 1.20 to 1.43; I² = 79%; 7 RCTs, n=1025). Of specific single adverse effects OCPs increased the risk of irregular bleeding (absolute risk difference [ARD] 24 %), headaches (ARD 0.14), nausea (ARD 0.07), and weight gain (ARD 0.06).

The evidence certainty was downgraded one time due to risk of bias and imprecision.

Table 1. Description of the included studies
Reference Study type Population Intervention and comparison Outcomes Risk of bias
RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis
«Schroll JB, Black AY, Farquhar C, et al. Combined ...»1 SR/MA of RCTs Women with primary dysmenorrhoea in outpatient settings Combined oral contraceptive pills vs placebo Post-treatment pain and adverse events Moderate
Table 2. Additional comments for included studies
Reference Comments
«Schroll JB, Black AY, Farquhar C, et al. Combined ...»1 Some risk of bias due to unclear study protocols on randomization and blinding in some of the studies and apparent lack of proper protocols in one old study. Most studies were sponsored by pharma industry.

Results

Table 3. Post treatment pain on a continuous pain score (TDS/MMDQ )
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C SMD (95% CI)
Level of evidence: moderate
The evidence was downgraded due to study limitations.
I= intervention; C=comparison; CI=confidence interval
«Schroll JB, Black AY, Farquhar C, et al. Combined ...»1 6 studies, 588 patients (328/260) 3-4 months N/A N/A -0.58 (-0.74,-0.41)
Table 4. Adverse effects
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Relative effect (95% CI)
Level of evidence: moderate
The evidence was downgraded due to study limitations
I= intervention; C=comparison; CI=confidence interval
«Schroll JB, Black AY, Farquhar C, et al. Combined ...»1 8 studies, 1025 patients (652/373) 3-4 months 536 (82%) 220 (59%) 1.31 [1.20,1.43]

References

  1. Schroll JB, Black AY, Farquhar C, et al. Combined oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2023;7(7):CD002120 «PMID: 37523477»PubMed